Add to Favorites Newsroom RSS Share
fb-shareWistar Institute
Philadelphia, PA USA

Our News on Newswise

New Insight Into the Balance Between the Tumor-suppressive and Tumor-promoting Effects of Cellular Senescence

Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.
18-Feb-2019 11:00 AM EST Add to Favorites

Combination of T Cell Therapy and Targeted Therapy as a Novel Strategy for Therapy-resistant Melanoma with Mutations in the BRAF Gene

Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.
14-Feb-2019 10:00 AM EST Add to Favorites

Federal Funding Fueled Growth of Wistar Science in 2018

The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.
11-Feb-2019 11:00 AM EST Add to Favorites

Engineered DNA Vaccine Protects Against Emerging Mayaro Virus Infection

A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.
5-Feb-2019 4:10 PM EST Add to Favorites

Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines

Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.
22-Jan-2019 4:30 PM EST Add to Favorites

newZika_shutterstock_2meg.jpg

First-in-Class DNA-encoded Monoclonal Antibody Therapy Rapidly Advances into the Clinic

Wistar, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. announce the FDA has approved the initiation of a first-in-human clinical trial investigating safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody...
8-Jan-2019 2:05 PM EST Add to Favorites

Engineered DNA-encoded PCSK9 Inhibitors May Provide an Effective Alternative for Treating High Cholesterol

Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.
5-Dec-2018 3:30 PM EST Add to Favorites

GabrilovichDmitry.jpg

Function of Neutrophils During Tumor Progression Unraveled

Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and...
15-Oct-2018 8:05 AM EDT Add to Favorites


see all news

Our YouTube Videos

About

As a nonprofit biomedical research institution, The Wistar Institute is committed to conducting basic research to benefit society and to training the next generation of scientists. Integrity in research is essential to expanding our knowledge of the basic biological processes fundamental to life. All faculty, staff, trainees, and students involved in research at The Wistar Institute are required to maintain the highest standards of ethical conduct in research and to adhere to the rules and regulations of federal agencies governing biomedical research. Faculty and senior research staff are expected to serve as mentors to trainees and students, teaching them the standards of ethical practice in research. Elements of integrity in research include intellectual honesty in conducting and reporting research, maintenance of accurate research records and results, proper allocation of credit among co-authors of studies, fairness in peer review, openness in communications and sharing of resources, transparency in potential conflicts of interest, humane care of animals in the conduct of research, and protection of human subjects in the conduct of research.

Contacts

Darien Sutton
Media Relations & Communications Manager

dsutton@wistar.org

215-898-3988

Tara Yates
Director of Communications
cancer

tyates@wistar.org

215-898-3826

Twitter twitter-icon

Chat now!